Jailendra Singh
Stock Analyst at Truist Securities
(0.58)
# 3,529
Out of 4,667 analysts
161
Total ratings
15.91%
Success rate
-32.02%
Average return
Main Sectors:
Stocks Rated by Jailendra Singh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DOCS Doximity | Maintains: Hold | $35 → $49 | $48.85 | +0.31% | 6 | Nov 14, 2024 | |
| PGNY Progyny | Downgrades: Hold | $26 → $19 | $13.98 | +35.91% | 9 | Nov 13, 2024 | |
| PRVA Privia Health Group | Maintains: Buy | $24 → $27 | $20.79 | +29.87% | 6 | Nov 8, 2024 | |
| IQV IQVIA Holdings | Maintains: Buy | $286 → $265 | $194.81 | +36.03% | 12 | Nov 4, 2024 | |
| ICLR ICON Public Limited Company | Maintains: Buy | $363 → $295 | $203.67 | +44.84% | 6 | Oct 28, 2024 | |
| MEDP Medpace Holdings | Maintains: Hold | $415 → $397 | $326.09 | +21.75% | 2 | Oct 14, 2024 | |
| ACCD Accolade | Maintains: Buy | $9 → $7.5 | $3.56 | +110.67% | 15 | Oct 9, 2024 | |
| PHR Phreesia | Maintains: Buy | $29 → $31 | $18.52 | +67.39% | 4 | Sep 6, 2024 | |
| VEEV Veeva Systems | Maintains: Hold | $197 → $207 | $210.42 | -1.63% | 5 | Sep 3, 2024 | |
| EVH Evolent Health | Maintains: Buy | $33 | $11.31 | +191.78% | 2 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $59 | $41.04 | +43.76% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $15 → $10 | $9.51 | +5.16% | 15 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $13 → $23 | $22.18 | +3.70% | 7 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $14 | $11.41 | +22.70% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $6.4 → $6.5 | $1.67 | +289.22% | 8 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $7.5 → $8 | $4.31 | +85.61% | 11 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $225 | $0.74 | +30,305.41% | 1 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $100 | $7.84 | +1,175.51% | 5 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $16 → $13 | $5.13 | +153.41% | 11 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $42 → $43 | $11.89 | +261.65% | 6 | Feb 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $24 | $4.10 | +485.37% | 2 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 → $4 | $2.60 | +54.14% | 4 | Feb 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $58 | $119.77 | -51.57% | 2 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $90 → $45 | $11.30 | +298.23% | 7 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $230 → $333 | $621.47 | -46.42% | 6 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $9 | $3.33 | +170.54% | 2 | May 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $22.23 | - | 3 | Jan 15, 2021 |
Doximity
Nov 14, 2024
Maintains: Hold
Price Target: $35 → $49
Current: $48.85
Upside: +0.31%
Progyny
Nov 13, 2024
Downgrades: Hold
Price Target: $26 → $19
Current: $13.98
Upside: +35.91%
Privia Health Group
Nov 8, 2024
Maintains: Buy
Price Target: $24 → $27
Current: $20.79
Upside: +29.87%
IQVIA Holdings
Nov 4, 2024
Maintains: Buy
Price Target: $286 → $265
Current: $194.81
Upside: +36.03%
ICON Public Limited Company
Oct 28, 2024
Maintains: Buy
Price Target: $363 → $295
Current: $203.67
Upside: +44.84%
Medpace Holdings
Oct 14, 2024
Maintains: Hold
Price Target: $415 → $397
Current: $326.09
Upside: +21.75%
Accolade
Oct 9, 2024
Maintains: Buy
Price Target: $9 → $7.5
Current: $3.56
Upside: +110.67%
Phreesia
Sep 6, 2024
Maintains: Buy
Price Target: $29 → $31
Current: $18.52
Upside: +67.39%
Veeva Systems
Sep 3, 2024
Maintains: Hold
Price Target: $197 → $207
Current: $210.42
Upside: -1.63%
Evolent Health
Aug 27, 2024
Maintains: Buy
Price Target: $33
Current: $11.31
Upside: +191.78%
Aug 9, 2024
Maintains: Buy
Price Target: $50 → $59
Current: $41.04
Upside: +43.76%
Aug 2, 2024
Maintains: Hold
Price Target: $15 → $10
Current: $9.51
Upside: +5.16%
Jul 18, 2024
Maintains: Hold
Price Target: $13 → $23
Current: $22.18
Upside: +3.70%
Jul 2, 2024
Maintains: Buy
Price Target: $17 → $14
Current: $11.41
Upside: +22.70%
May 24, 2024
Maintains: Hold
Price Target: $6.4 → $6.5
Current: $1.67
Upside: +289.22%
Mar 1, 2024
Maintains: Hold
Price Target: $7.5 → $8
Current: $4.31
Upside: +85.61%
Sep 7, 2022
Initiates: Hold
Price Target: $225
Current: $0.74
Upside: +30,305.41%
Sep 7, 2022
Initiates: Hold
Price Target: $100
Current: $7.84
Upside: +1,175.51%
May 4, 2022
Maintains: Neutral
Price Target: $16 → $13
Current: $5.13
Upside: +153.41%
Feb 28, 2022
Maintains: Neutral
Price Target: $42 → $43
Current: $11.89
Upside: +261.65%
Feb 24, 2022
Maintains: Neutral
Price Target: $30 → $24
Current: $4.10
Upside: +485.37%
Feb 8, 2022
Downgrades: Neutral
Price Target: $14 → $4
Current: $2.60
Upside: +54.14%
Feb 4, 2022
Maintains: Neutral
Price Target: $60 → $58
Current: $119.77
Upside: -51.57%
Jan 7, 2022
Downgrades: Underperform
Price Target: $90 → $45
Current: $11.30
Upside: +298.23%
Jan 7, 2022
Upgrades: Outperform
Price Target: $230 → $333
Current: $621.47
Upside: -46.42%
May 19, 2021
Maintains: Neutral
Price Target: $10 → $9
Current: $3.33
Upside: +170.54%
Jan 15, 2021
Downgrades: Underperform
Price Target: n/a
Current: $22.23
Upside: -